ArticleOncology letters2021

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres.

Lu Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.